Your browser doesn't support javascript.
loading
A non-functional galanin receptor-2 in a multiple sclerosis patient.
Garcia-Rosa, Sheila; Trivella, Daniela Bb; Marques, Vanessa D; Serafim, Rodolfo B; Pereira, José Gc; Lorenzi, Julio Cc; Molfetta, Greice A; Christo, Paulo P; Olival, Guilherme S; Marchitto, Vania Bt; Brum, Doralina G; Sabedot, Thais S; Noushmehr, Houtan; Farias, Alessandro S; Santos, Leonilda Mb; Nogueira-Machado, José A; Souza, Jorge Es; Romano, Camila M; Conde, Rodrigo M; Santos, Antonio C; Guerreiro, Carlos T; Schreuder, Willem H; Gleber-Netto, Frederico O; Amorim, Maria; Valieris, Renan; Silva, Israel Tojal da; Silva, Wilson A; Nunes, Diana N; Oliveira, Paulo Sl; Valente, Valeria; Arruda, Maria Augusta; Hill, Stephen J; Barreira, Amilton A; Dias-Neto, Emmanuel.
Afiliação
  • Garcia-Rosa S; Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Trivella DB; Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.
  • Marques VD; CAPES-University of Nottingham Programme in Drug Discovery, Queen's Medical Centre University of Nottingham, Nottingham, NG7 2UH, United Kingdom.
  • Serafim RB; Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
  • Pereira JG; Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Lorenzi JC; Department of Cellular and Molecular Biology, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Molfetta GA; Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.
  • Christo PP; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Olival GS; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Marchitto VB; Curso de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.
  • Brum DG; Neurosciences Research Group, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
  • Sabedot TS; Neurosciences Research Group, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
  • Noushmehr H; Department of Neurology, Psychology and Psychiatry, School of Medicine of Botucatu, University of State of São Paulo (UNESP), Botucatu, SP, Brazil.
  • Farias AS; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Santos LM; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Nogueira-Machado JA; Neuroimmunology Unit, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
  • Souza JE; Neuroimmunology Unit, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
  • Romano CM; Curso de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.
  • Conde RM; Instituto Metrópole Digital, Federal University of Rio Grande do Norte, Natal, RN, Brazil.
  • Santos AC; Lab. Virology (LIM52), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil.
  • Guerreiro CT; Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Schreuder WH; Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Gleber-Netto FO; Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Amorim M; Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Valieris R; Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Silva ITD; Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Silva WA; Laboratory of Bioinformatics and Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil.
  • Nunes DN; Laboratory of Bioinformatics and Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil.
  • Oliveira PS; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
  • Valente V; Center for Medical Genomics at HCFMRP, Universidade de Sao Paulo (USP), Ribeirão Preto, Brazil.
  • Arruda MA; Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Hill SJ; Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.
  • Barreira AA; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil.
  • Dias-Neto E; CAPES-University of Nottingham Programme in Drug Discovery, Queen's Medical Centre University of Nottingham, Nottingham, NG7 2UH, United Kingdom.
Pharmacogenomics J ; 19(1): 72-82, 2019 02.
Article em En | MEDLINE | ID: mdl-30131588
ABSTRACT
Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease that affects approximately 2.5 million people globally. Even though the etiology of MS remains unknown, it is accepted that it involves a combination of genetic alterations and environmental factors. Here, after performing whole exome sequencing, we found a MS patient harboring a rare and homozygous single nucleotide variant (SNV; rs61745847) of the G-protein coupled receptor (GPCR) galanin-receptor 2 (GALR2) that alters an important amino acid in the TM6 molecular toggle switch region (W249L). Nuclear magnetic resonance imaging showed that the hypothalamus (an area rich in GALR2) of this patient exhibited an important volumetric reduction leading to an enlarged third ventricle. Ex vivo experiments with patient-derived blood cells (AKT phosphorylation), as well as studies in recombinant cell lines expressing the human GALR2 (calcium mobilization and NFAT mediated gene transcription), showed that galanin (GAL) was unable to stimulate cell signaling in cells expressing the variant GALR2 allele. Live cell confocal microscopy showed that the GALR2 mutant receptor was primarily localized to intracellular endosomes. We conclude that the W249L SNV is likely to abrogate GAL-mediated signaling through GALR2 due to the spontaneous internalization of this receptor in this patient. Although this homozygous SNV was rare in our MS cohort (1262 cases), our findings raise the potential importance of impaired neuroregenerative pathways in the pathogenesis of MS, warrant future studies into the relevance of the GAL/GALR2 axis in MS and further suggest the activation of GALR2 as a potential therapeutic route for this disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Galanina / Receptor Tipo 2 de Galanina / Esclerose Múltipla Tipo de estudo: Observational_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Galanina / Receptor Tipo 2 de Galanina / Esclerose Múltipla Tipo de estudo: Observational_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article